Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease

Leukemia

Volumn 23, Issue 4, 2009, Pages 698-707

  Jardin, F ^a   Callanan, M ^b,c   Penther, D ^a   Ruminy, P ^a   Troussard, X ^d   Kerckaert, J P ^e   Figeac, M ^e   Parmentier, F ^a   Rainville, V ^a   Vaida, I ^f   Bertrand, P ^a   Duval, A B ^g   Picquenot, J M ^a   Chaperot, L ^h   Marolleau, J P ^f   Plumas, J ^h   Tilly, H ^a   Bastard, C ^a  

^a CENTRE HENRI BECQUEREL   (France)

^b Molecular and Cellular Haematology Unit   (France)

^c INSERM   (France)

^d CHU CÔTE DE NACRE   (France)

^e JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^f AMIENS UNIVERSITY HOSPITAL   (France)

^g HÔPITAL CHARLES NICOLLE   (France)

^h UNIV GRENOBLE ALPES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD56 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUDARABINE; IFOSFAMIDE; METHOTREXATE; MICRORNA; MYC PROTEIN; PREDNISONE; PROTEIN P53; TRANSCRIPTION FACTOR E2F; VINCRISTINE;

ADULT; AGED; ALLELIC IMBALANCE; ARTICLE; BLASTIC NK CELL LYMPHOMA; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CHROMOSOME 12P; CHROMOSOME 13; CHROMOSOME 17P; CHROMOSOME 8Q; CHROMOSOME 9; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE FUNCTION; GENE LOSS; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 64849117150     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.359     Document Type: Article

References (29)

1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH et al WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
2. Feuillard J, Jacob MC, Valensi F, Maynadie M, Gressin R, Chaperot L et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 2002; 99: 1556-1563.
3. Garnache-Ottou F, Feuillard J, Saas P. Plasmacytoid dendritic cell leukaemia/lymphoma: Towards a well defined entity? Br J Haematol 2007; 136: 539-548.
4. Petrella T, Bagot M, Willemze R, Beylot-Barry M, Vergier B, Delaunay M et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): A review. Am J Clin Pathol 2005; 123: 662-675.
5. Pilichowska ME, Fleming MD, Pinkus JL, Pinkus GS. CD4+/CD56+ hematodermic neoplasm ('blastic natural killer cell lymphoma'): neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon. Am J Clin Pathol 2007; 128: 445-453.
6. Herling M, Jones D. CD4+/CD56+ hematodermic tumor: The features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol 2007; 127: 687-700.
7. Leroux D, Mugneret F, Callanan M, Radford-Weiss I, Dastugue N, Feuillard J et al. CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: A study of 21 cases by the Groupe Francais de Cytogenetique Hematologique. Blood 2002; 99: 4154-4159.
8. Dijkman R, van Doorn R, Szuhai K, Willemze R, Vermeer MH, Tensen CP. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood 2007; 109: 1720-1727.
9. Chaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001; 97: 3210-3217.
10. Chaperot L, Blum A, Manches O, Lui G, Angel J, Molens JP et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol 2006; 176: 248-255.
11. Bastard C, Raux G, Fruchart C, Parmentier F, Vaur D, Penther D et al Comparison of a quantitative PCR method with FISH for the assessment of the four aneuploidies commonly evaluated in CLL patients. Leukemia 2007; 21: 1460-1463.
12. Quintanilla-Martinez L, Kremer M, Keller G, Nathrath M, Gamboa-Dominguez A, Meneses A et al. p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: Association with large cell morphology and advanced disease. Am J Pathol 2001; 159: 2095-2105.
13. Huppi K, Volfovsky N, Runfola T, Jones TL, Mackiewicz M, Martin SE et al. The identification of microRNAs in a genomically unstable region of human chromosome 8q24. Mol Cancer Res 2008; 6: 212-221.
14. Rucker FG, Bullinger L, Schwaenen C, Lipka DB, Wessendorf S, Frohling S et al. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 2006; 24: 3887-3894.
15. Hangaishi A, Ogawa S, Imamura N, Miyawaki S, Miura Y, Uike N et al Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood 1996; 87 4949-4958.
16. Trovo-Marqui AB, Tajara EH. Neurofibromin: A general outlook. Clin Genet 2006; 70: 1-13.
17. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007; 450: 893-898.
18. Dallol A, Da Silva NF, Viacava P, Minna JD, Bieche I, Maher ER et al SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res 2002; 62: 5874-5880.
19. Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijima T. Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res 2006; 66: 6080-6086.
20. Her C, Zhao N, Wu X, Tompkins JD. MutS homologues hMSH4 and hMSH5: diverse functional implications in humans. Front Biosci 2007; 12: 905-911.
21. Tavera-Mendoza LE, Wang TT, White JH. p19INK4D and cell death. Cell Cycle 2006; 5: 596-598.
22. Niida H, Nakanishi M. DNA damage checkpoints in mammals. Mutagenesis 2006; 21: 3-9.
23. Davies SR, Watkins G, Mansel RE, Jiang WG. Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2, and WISP-3 in human breast cancer. Ann Surg Oncol 2007; 14: 1909-1918.
24. Hamaguchi M, Meth JL, von Klitzing C, Wei W, Esposito D, Rodgers L et al. DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci USA 2002; 99: 13647-13652.
25. Radulescu RT. One for all and all for one: RB defends the cell while IDE, PTEN and IGFBP-7 antagonize insulin and IGFs to protect RB. Med Hypotheses 2007; 69: 1018-1020.
26. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40: 43-50.
27. Martinez I, Gardiner AS, Board KF,Monzon FA, Edwards RP, Khan SA. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 2008; 27: 2575-2582.
28. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P et al MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67: 8699-8707.
29. Gauwerky CE, Huebner K, Isobe M, Nowell PC, Croce CM. Activation of MYC in a masked t(8;17) translocation results in an aggressive B-cell leukemia. Proc Natl Acad Sci USA 1989; 86: 8867-8871.